Cannabidiol

Mula sa Wikipediang Tagalog, ang malayang ensiklopedya
Jump to navigation Jump to search
Cannabidiol
Cannabidiol Structural formula V1.svg
CBD-3D-balls.png
Datos Klinikal
Mga tatak pangkalakal Epidiolex
AHFS/Drugs.com International Drug Names
Kodigong ATC
Estadong Legal
Estadong legal
Datos Parmakokinetiko
Bioavailability 13–19% (pambibig),[2] 11–45% (turan 31%; langhap)[3]
Biyolohikal na hating-buhay 9 na oras[2]
Mga pangkilala
Bilang ng CAS
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ECHA InfoCard 100.215.986
Datos Kemikal at Pisikal
Pormula C21H30O2
Bigat Molar 314.4636
Modelong 3D (Jmol)
Punto ng pagkatunaw 66 °C (151 °F)
Punto ng pagkulo 180 °C (356 °F)
(hangganan: 160–180 °C)[4]
 NY (ano ito?)  (patunayan)

Ang Cannabidiol (CBD) ang isa sa mga 85 cannabinoid na matatagpuan sa halamang cannabis o marijuana.[5] Ito ang pangunahing sangkap ng halaman na ikalawa sa THC at kumakatawan sa hanggang 40% nito.[6] Kumpara sa THC, ang cannabidiol ay mas kaunting sikoaktibo at itinuturing na may mas malawak na sakop ng mga paggamot medikal kesa sa THC [7] kabilang sa epilepsy,[8] multiple sclerosis spasms,[9] anxiety disorders, bipolar Disorder,[7] schizophrenia,[10] nausea, kombulsiyon at pamamaga gayundin sa pagpigil ng paglago ng selulang kanser.[11] Ang Cannabidiol ay nagpakita ng mga epektong sedatibo o pampakalma sa mga pagsubok sa hayop.[12] Ang ibang pagsasaliksik ay nagpapakita na ito ay nagpapataas ng pagiging alerto.[13] Ang Cannabidiol ay naipakitang nagbawas ng paglago ng mga selulang kanser sa suso in vitro at nagbawas ng kanilang pagsalakay.[14]

Mga sanggunian[baguhin | baguhin ang batayan]

  1. DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").
  2. 2.0 2.1 "Cannabidiol: an overview of some pharmacological aspects". J Clin Pharmacol 42 (11 Suppl): 11S–19S. November 2002. doi:10.1177/0091270002238789. PMID 12412831. 
  3. "Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders". Phytother Res 23 (5): 597–602. May 2009. doi:10.1002/ptr.2625. PMID 18844286. 
  4. Padron:MEDRS "Cannabis and cannabis extracts: greater than the sum of their parts?". Journal of Cannabis Therapeutics 1 (3/4): 103–132. 2001. doi:10.1300/J175v01n03_08. http://www.cannabis-med.org/data/pdf/2001-03-04-7.pdf. 
  5. El-Alfy, Abir T, et al. (Jun 2010). "Antidepressant-like effect of delta-9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.". Pharmacology Biochemistry and Behavior 95 (4): 434–42. doi:10.1016/j.pbb.2010.03.004. . PMID 20332000. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2866040. 
  6. Grlić, Ljubiša (1962). "A comparative study on some chemical and biological characteristics of various samples of cannabis resin". Bulletin on Narcotics (UNODC) (3): 37–46. http://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1962-01-01_3_page005.html. 
  7. 7.0 7.1 Ashton, C.H., Moore, P. B., Gallagher, P., Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology (U.K).
  8. PMID 22520455 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  9. PMID 21449980 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  10. Zuardi, A.W; J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães (2006). "Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug" (PDF). Braz. J. Med. Biol. Res. 39 (4): 421–429. doi:10.1590/S0100-879X2006000400001. PMID 16612464. http://www.scielo.br/pdf/bjmbr/v39n4/6164.pdf. 
  11. Mechoulam, R.; M. Peters, Murillo-Rodriguez (21 Aug 2007). "Cannabidiol - recent advances". Chemistry & Biodiversity 4 (8): 1678–1692. doi:10.1002/cbdv.200790147. PMID 17712814. http://www3.interscience.wiley.com/journal/115806131/abstract. 
  12. Pickens JT (1981). "Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content". Br. J. Pharmacol. 72 (4): 649–56. doi:10.1111/j.1476-5381.1981.tb09145.x. . PMID 6269680. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2071638. 
  13. Nicholson, AN; C Turner, BM Stone, and PJ Robson (June 2004). "Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults". J Clin Psychopharmacol 24 (3): 305–13. doi:10.1097/01.jcp.0000125688.05091.8f. ISSN 0271-0749. PMID 15118485. http://safeaccess.ca/research/pdf/Nicholson_CBME_Sleep.pdf. 
  14. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). "Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells". Mol. Cancer Ther. 6 (11): 2921–7. doi:10.1158/1535-7163.MCT-07-0371. PMID 18025276.